Your Industry
Pharmaceuticals
Accelerating Predictable, Profitable Performance in Pharmaceuticals
We accelerate performance across manufacturing, supply chains, and global operations, turning complexity into controlled, measurable performance.
The sector is operating under sustained pressure:
- Supply chain disruption and product availability challenges
- Rising manufacturing and compliance costs
- Demand variability across global markets
- Margin pressure and pricing constraints
At the same time, increasing regulatory requirements are adding complexity across operations.
Brooks International addresses CEO challenges and translates growth into predictable, profitable performance.
Where We Drive Operational and Financial Performance
Value creation in Pharmaceuticals is realized when scientific innovation, regulated processes, specialized assets, and complex supply networks translate into reliable, compliant product availability.
For leaders managing API, formulation, fill-finish, packaging, or medicine manufacturing operations, EBITDA improvement is driven by shorter cycle times, stronger right-first-time execution, quality and compliance control, lower conversion cost, faster inventory release, and disciplined scale-up or capital execution.
Manufacturing Throughput and Batch Cycle Performance
Improve production flow across API, formulation, fill-finish, packaging, or related medicine manufacturing operations by reducing cycle time, queue time, process variation, schedule misses, and avoidable batch delays.
Value Impact
Improves revenue availability, increases capacity utilization, reduces cost per batch, and strengthens operating predictability across regulated manufacturing environments.
Right-First-Time Quality and Batch Release Performance
Strengthen quality execution by improving documentation accuracy, deviation prevention, investigation closure, batch record review, testing turnaround, and release readiness across production and quality teams.
Value Impact
Reduces rework, rejected batches, inventory holds, and release delays while protecting margin, cash conversion, and customer or patient supply commitments.
GMP Compliance, Data Integrity, and Inspection Readiness
Improve compliance performance by strengthening procedural adherence, data integrity, training effectiveness, audit readiness, CAPA execution, and escalation routines across sites, functions, and product families.
Value Impact
Reduces regulatory risk, protects license to operate, improves execution consistency, and prevents financial exposure from avoidable compliance failures.
Asset Reliability, Maintenance, and Process Uptime
Increase uptime across critical production, utility, laboratory, packaging, and cleanroom assets through stronger maintenance planning, calibration readiness, reliability routines, backlog control, and execution coordination.
Value Impact
Reduces unplanned downtime, emergency work, capacity loss, and maintenance cost leakage while improving asset utilization and supply reliability.
Supply Chain, Inventory, and Product Availability
Improve the flow of raw materials, APIs, excipients, components, packaging, intermediates, finished goods, and quality-released inventory while reducing shortages, excess stock, expediting, and working capital drag.
Value Impact
Protects product availability, improves cash generation, reduces service risk, and strengthens fulfillment reliability across internal and external supply networks.
Technology Transfer, Scale-Up, and Capital Execution
Strengthen governance over tech transfer, validation, new product introduction, capacity expansion, automation, facility upgrades, and compliance-related investments from approval through execution and benefit realization.
Value Impact
Accelerates revenue activation, improves capital productivity, reduces launch and scale-up risk, and ensures investment translates into measurable operational and financial outcomes.
All performance improvement is delivered through the Brooks International Performance Engine™ - our system for connecting strategy, financial outcomes, and execution.
Success Stories
Benefit from our deep experience in delivering accelerated value in complex operational environments across Pharmaceuticals
Proven Results in Pharmaceuticals
Private Equity Owned European Pharmaceutical Manufacturer Restores >30% EBITDA Margin and Production Stability Through SIOP, Process Control, and Crop-to-Plant Yield Optimization
- 30%+ EBITDA Margin Achieved
- 12% Daily Production Increase
- 80% QC-Associated Downtime Reduction
- 22% Lost Hours Reduction
Leading Pharmaceutical Excipients and Biopolymer Supplier Strengthens Plant Competitiveness and Delivers 4:1 First-Year ROI
- 40% Contractor Labor Expense Reduction
- 4:1 First-Year Return on Investment
- 28% Non-Productive Staffing Reduction
- 20% Overtime Reduction
- 18% Fixed Labor Cost Reduction